| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 148 | 2026 | 1219 | 10.530 |
Why?
|
| Heart Failure | 118 | 2026 | 2323 | 8.190 |
Why?
|
| Acute Coronary Syndrome | 48 | 2026 | 246 | 7.470 |
Why?
|
| Myocardial Infarction | 66 | 2026 | 998 | 7.200 |
Why?
|
| Troponin I | 36 | 2026 | 122 | 5.810 |
Why?
|
| Natriuretic Peptide, Brain | 45 | 2026 | 324 | 4.860 |
Why?
|
| Troponin T | 30 | 2026 | 254 | 4.100 |
Why?
|
| Hyperkalemia | 8 | 2023 | 69 | 4.080 |
Why?
|
| Pulmonary Embolism | 25 | 2025 | 191 | 3.780 |
Why?
|
| Chest Pain | 31 | 2022 | 123 | 3.680 |
Why?
|
| Dyspnea | 24 | 2026 | 159 | 3.190 |
Why?
|
| Rivaroxaban | 16 | 2020 | 48 | 3.160 |
Why?
|
| Electrocardiography | 56 | 2021 | 975 | 2.950 |
Why?
|
| Biomarkers | 88 | 2026 | 3384 | 2.820 |
Why?
|
| Acute Disease | 74 | 2026 | 1148 | 2.610 |
Why?
|
| Factor Xa Inhibitors | 11 | 2020 | 59 | 2.390 |
Why?
|
| Risk Assessment | 58 | 2024 | 3675 | 2.370 |
Why?
|
| Hospitalization | 37 | 2025 | 1930 | 2.240 |
Why?
|
| Patient Discharge | 24 | 2026 | 513 | 2.190 |
Why?
|
| Middle Aged | 194 | 2026 | 28393 | 2.170 |
Why?
|
| Aged | 179 | 2026 | 20883 | 2.120 |
Why?
|
| Troponin | 15 | 2024 | 69 | 1.950 |
Why?
|
| Humans | 338 | 2026 | 130481 | 1.820 |
Why?
|
| Prospective Studies | 80 | 2026 | 6451 | 1.800 |
Why?
|
| Male | 232 | 2026 | 64495 | 1.780 |
Why?
|
| Female | 231 | 2026 | 70399 | 1.670 |
Why?
|
| Emergency Medicine | 13 | 2016 | 177 | 1.620 |
Why?
|
| Length of Stay | 33 | 2024 | 1398 | 1.550 |
Why?
|
| Guideline Adherence | 18 | 2021 | 389 | 1.550 |
Why?
|
| Hemorrhage | 18 | 2024 | 490 | 1.550 |
Why?
|
| Peptide Fragments | 14 | 2026 | 687 | 1.540 |
Why?
|
| Practice Guidelines as Topic | 29 | 2017 | 1289 | 1.520 |
Why?
|
| Hospital Mortality | 31 | 2022 | 1059 | 1.510 |
Why?
|
| Patient Readmission | 14 | 2025 | 433 | 1.500 |
Why?
|
| Registries | 44 | 2025 | 1617 | 1.490 |
Why?
|
| Emergency Medical Services | 14 | 2021 | 387 | 1.470 |
Why?
|
| Aged, 80 and over | 77 | 2025 | 6793 | 1.470 |
Why?
|
| Anticoagulants | 17 | 2024 | 602 | 1.470 |
Why?
|
| Antihypertensive Agents | 10 | 2015 | 417 | 1.440 |
Why?
|
| Emergency Treatment | 8 | 2020 | 82 | 1.360 |
Why?
|
| Hypertension | 14 | 2020 | 1347 | 1.340 |
Why?
|
| Vasodilator Agents | 12 | 2015 | 198 | 1.330 |
Why?
|
| Venous Thromboembolism | 9 | 2025 | 192 | 1.310 |
Why?
|
| Galectin 3 | 4 | 2015 | 32 | 1.270 |
Why?
|
| Polymers | 3 | 2023 | 104 | 1.250 |
Why?
|
| Cardiology | 11 | 2024 | 513 | 1.230 |
Why?
|
| Sensitivity and Specificity | 36 | 2026 | 2089 | 1.220 |
Why?
|
| Triage | 8 | 2025 | 143 | 1.200 |
Why?
|
| Adult | 86 | 2026 | 31145 | 1.130 |
Why?
|
| Glycopeptides | 7 | 2018 | 26 | 1.100 |
Why?
|
| Atrial Natriuretic Factor | 10 | 2017 | 43 | 1.070 |
Why?
|
| Atrial Fibrillation | 8 | 2018 | 737 | 1.050 |
Why?
|
| Stroke | 9 | 2020 | 1056 | 1.040 |
Why?
|
| Mental Disorders | 3 | 2025 | 902 | 1.040 |
Why?
|
| Potassium | 5 | 2020 | 268 | 1.020 |
Why?
|
| Pyridines | 4 | 2015 | 258 | 0.990 |
Why?
|
| Predictive Value of Tests | 36 | 2023 | 2294 | 0.960 |
Why?
|
| Prognosis | 55 | 2024 | 4863 | 0.960 |
Why?
|
| United States | 66 | 2025 | 11880 | 0.930 |
Why?
|
| Warfarin | 10 | 2019 | 123 | 0.900 |
Why?
|
| Creatine Kinase, MB Form | 10 | 2017 | 21 | 0.860 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2017 | 28 | 0.860 |
Why?
|
| Retrospective Studies | 58 | 2025 | 17529 | 0.860 |
Why?
|
| Early Diagnosis | 7 | 2017 | 189 | 0.850 |
Why?
|
| Stethoscopes | 1 | 2024 | 3 | 0.840 |
Why?
|
| Natriuretic Agents | 6 | 2011 | 28 | 0.840 |
Why?
|
| Quality of Health Care | 10 | 2020 | 408 | 0.840 |
Why?
|
| Hemodynamics | 7 | 2017 | 805 | 0.820 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2021 | 302 | 0.820 |
Why?
|
| Infusions, Intravenous | 14 | 2017 | 535 | 0.820 |
Why?
|
| Algorithms | 12 | 2025 | 1663 | 0.820 |
Why?
|
| Stroke Volume | 15 | 2021 | 534 | 0.810 |
Why?
|
| Immunoassay | 3 | 2025 | 126 | 0.810 |
Why?
|
| Accreditation | 5 | 2021 | 85 | 0.810 |
Why?
|
| Coronary Disease | 13 | 2006 | 628 | 0.770 |
Why?
|
| Dabigatran | 3 | 2019 | 26 | 0.770 |
Why?
|
| Syncope | 6 | 2022 | 52 | 0.760 |
Why?
|
| Phonocardiography | 4 | 2009 | 4 | 0.760 |
Why?
|
| Time-to-Treatment | 5 | 2018 | 210 | 0.750 |
Why?
|
| Time Factors | 39 | 2021 | 6199 | 0.750 |
Why?
|
| Diuretics | 13 | 2021 | 157 | 0.750 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 155 | 0.740 |
Why?
|
| Protein Precursors | 4 | 2017 | 139 | 0.720 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2020 | 363 | 0.710 |
Why?
|
| Mass Screening | 3 | 2025 | 808 | 0.710 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2018 | 643 | 0.690 |
Why?
|
| Blood Pressure | 9 | 2017 | 1344 | 0.680 |
Why?
|
| Societies, Medical | 9 | 2016 | 798 | 0.670 |
Why?
|
| Point-of-Care Systems | 5 | 2024 | 212 | 0.660 |
Why?
|
| Noninvasive Ventilation | 2 | 2018 | 32 | 0.650 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2020 | 139 | 0.650 |
Why?
|
| Silicates | 1 | 2020 | 7 | 0.640 |
Why?
|
| Treatment Outcome | 38 | 2025 | 12850 | 0.630 |
Why?
|
| Severity of Illness Index | 22 | 2017 | 3031 | 0.630 |
Why?
|
| Costs and Cost Analysis | 3 | 2017 | 151 | 0.620 |
Why?
|
| Observation | 9 | 2017 | 40 | 0.620 |
Why?
|
| Angina Pectoris | 8 | 2016 | 56 | 0.620 |
Why?
|
| Angioplasty, Balloon, Coronary | 10 | 2009 | 163 | 0.610 |
Why?
|
| Pilot Projects | 11 | 2025 | 1449 | 0.600 |
Why?
|
| Diabetes Mellitus | 7 | 2022 | 890 | 0.580 |
Why?
|
| Cardiography, Impedance | 3 | 2008 | 7 | 0.570 |
Why?
|
| Critical Pathways | 5 | 2017 | 77 | 0.570 |
Why?
|
| Decision Making | 4 | 2014 | 705 | 0.570 |
Why?
|
| Adrenomedullin | 6 | 2017 | 82 | 0.570 |
Why?
|
| Disease Management | 8 | 2021 | 556 | 0.570 |
Why?
|
| Labetalol | 3 | 2015 | 10 | 0.570 |
Why?
|
| Bronchodilator Agents | 3 | 2025 | 156 | 0.560 |
Why?
|
| Nicardipine | 3 | 2015 | 15 | 0.560 |
Why?
|
| Coronary Care Units | 4 | 2013 | 34 | 0.560 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 292 | 0.560 |
Why?
|
| Renal Insufficiency | 8 | 2014 | 256 | 0.560 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2018 | 118 | 0.540 |
Why?
|
| Renin-Angiotensin System | 3 | 2020 | 104 | 0.530 |
Why?
|
| Follow-Up Studies | 30 | 2021 | 5164 | 0.530 |
Why?
|
| ROC Curve | 15 | 2025 | 611 | 0.530 |
Why?
|
| Cardiovascular Diseases | 11 | 2021 | 2100 | 0.520 |
Why?
|
| Intracranial Hemorrhages | 2 | 2019 | 80 | 0.520 |
Why?
|
| Coronary Artery Disease | 8 | 2023 | 889 | 0.520 |
Why?
|
| Heart Failure, Systolic | 2 | 2009 | 35 | 0.520 |
Why?
|
| Patient Admission | 11 | 2018 | 186 | 0.510 |
Why?
|
| Double-Blind Method | 12 | 2020 | 1623 | 0.510 |
Why?
|
| Hospital Costs | 4 | 2017 | 182 | 0.490 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 483 | 0.490 |
Why?
|
| Reference Values | 8 | 2026 | 677 | 0.490 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 461 | 0.470 |
Why?
|
| Risk Factors | 38 | 2023 | 10949 | 0.470 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2019 | 228 | 0.460 |
Why?
|
| Furosemide | 2 | 2021 | 36 | 0.460 |
Why?
|
| Healthcare Disparities | 4 | 2017 | 512 | 0.450 |
Why?
|
| Blood Chemical Analysis | 3 | 2020 | 80 | 0.450 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2016 | 80 | 0.450 |
Why?
|
| Morphine | 3 | 2017 | 80 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 566 | 0.450 |
Why?
|
| Ventricular Function, Left | 5 | 2021 | 544 | 0.440 |
Why?
|
| Comorbidity | 13 | 2019 | 1584 | 0.440 |
Why?
|
| Intracranial Embolism | 3 | 2020 | 24 | 0.430 |
Why?
|
| Multicenter Studies as Topic | 8 | 2023 | 299 | 0.430 |
Why?
|
| Heart Sounds | 4 | 2006 | 5 | 0.430 |
Why?
|
| Sepsis | 2 | 2020 | 495 | 0.420 |
Why?
|
| Peroxidase | 2 | 2011 | 63 | 0.420 |
Why?
|
| Calcitonin | 1 | 2014 | 29 | 0.420 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2020 | 276 | 0.410 |
Why?
|
| Calcium Channel Blockers | 2 | 2014 | 108 | 0.410 |
Why?
|
| Limit of Detection | 7 | 2025 | 74 | 0.410 |
Why?
|
| Quality Assurance, Health Care | 4 | 2013 | 205 | 0.410 |
Why?
|
| Body Temperature | 1 | 2014 | 126 | 0.410 |
Why?
|
| Angina, Unstable | 8 | 2023 | 49 | 0.400 |
Why?
|
| Heart Auscultation | 3 | 2010 | 7 | 0.400 |
Why?
|
| Blood Pressure Determination | 2 | 2014 | 119 | 0.400 |
Why?
|
| Age Factors | 15 | 2026 | 2828 | 0.390 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 97 | 0.390 |
Why?
|
| Hypothermia, Induced | 1 | 2014 | 171 | 0.380 |
Why?
|
| Brain Injuries, Traumatic | 3 | 2026 | 323 | 0.380 |
Why?
|
| Cohort Studies | 14 | 2025 | 5049 | 0.370 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2017 | 214 | 0.360 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2014 | 325 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 1272 | 0.360 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 844 | 0.360 |
Why?
|
| Evidence-Based Medicine | 8 | 2018 | 644 | 0.360 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2011 | 19 | 0.350 |
Why?
|
| Diagnosis, Differential | 14 | 2025 | 1878 | 0.350 |
Why?
|
| Myocardial Revascularization | 6 | 2020 | 100 | 0.350 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 420 | 0.350 |
Why?
|
| Creatine Kinase | 7 | 2003 | 64 | 0.340 |
Why?
|
| Antipyretics | 1 | 2011 | 7 | 0.340 |
Why?
|
| Clinical Trials as Topic | 8 | 2014 | 1122 | 0.340 |
Why?
|
| Ambulatory Care | 4 | 2021 | 401 | 0.340 |
Why?
|
| Insulin | 3 | 2023 | 1140 | 0.340 |
Why?
|
| Health Care Costs | 7 | 2019 | 406 | 0.330 |
Why?
|
| Heart Arrest | 3 | 2014 | 380 | 0.330 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 642 | 0.330 |
Why?
|
| Guidelines as Topic | 4 | 2016 | 202 | 0.330 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2020 | 20 | 0.320 |
Why?
|
| Continuity of Patient Care | 2 | 2013 | 144 | 0.320 |
Why?
|
| Confidence Intervals | 7 | 2010 | 269 | 0.320 |
Why?
|
| Acetaminophen | 1 | 2011 | 99 | 0.310 |
Why?
|
| Mortality | 4 | 2019 | 259 | 0.310 |
Why?
|
| Research Design | 7 | 2017 | 715 | 0.310 |
Why?
|
| Auscultation | 2 | 2006 | 3 | 0.310 |
Why?
|
| Critical Illness | 1 | 2014 | 621 | 0.310 |
Why?
|
| Exercise Test | 4 | 2020 | 238 | 0.300 |
Why?
|
| Logistic Models | 16 | 2018 | 1801 | 0.300 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 4 | 2009 | 46 | 0.300 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 56 | 0.300 |
Why?
|
| Clinical Protocols | 6 | 2017 | 230 | 0.300 |
Why?
|
| Asthma | 2 | 2017 | 921 | 0.290 |
Why?
|
| Professional Practice Gaps | 2 | 2020 | 14 | 0.290 |
Why?
|
| Incidence | 9 | 2019 | 3317 | 0.280 |
Why?
|
| Fibrinolytic Agents | 3 | 2018 | 190 | 0.280 |
Why?
|
| Cardiovascular Agents | 3 | 2014 | 88 | 0.280 |
Why?
|
| Fever | 1 | 2011 | 309 | 0.280 |
Why?
|
| Biological Assay | 2 | 2020 | 106 | 0.280 |
Why?
|
| Isoenzymes | 5 | 2003 | 211 | 0.280 |
Why?
|
| Lung Diseases | 2 | 2011 | 396 | 0.280 |
Why?
|
| Myocardial Reperfusion | 2 | 2011 | 53 | 0.270 |
Why?
|
| Sex Factors | 10 | 2020 | 1339 | 0.270 |
Why?
|
| Nitroglycerin | 3 | 2010 | 23 | 0.270 |
Why?
|
| Administration, Oral | 4 | 2015 | 708 | 0.270 |
Why?
|
| Reproducibility of Results | 9 | 2025 | 2900 | 0.270 |
Why?
|
| Aspirin | 6 | 2020 | 214 | 0.270 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 775 | 0.270 |
Why?
|
| Spain | 7 | 2025 | 58 | 0.260 |
Why?
|
| Kidney | 2 | 2017 | 1277 | 0.260 |
Why?
|
| Cardiac Catheterization | 8 | 2020 | 623 | 0.260 |
Why?
|
| Galectins | 2 | 2019 | 24 | 0.260 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 2 | 2019 | 22 | 0.260 |
Why?
|
| Advisory Committees | 3 | 2016 | 148 | 0.250 |
Why?
|
| Insurance Claim Review | 2 | 2017 | 26 | 0.250 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 159 | 0.250 |
Why?
|
| Diagnostic Imaging | 4 | 2009 | 307 | 0.250 |
Why?
|
| Consensus | 4 | 2019 | 528 | 0.250 |
Why?
|
| Heart Rate | 3 | 2021 | 575 | 0.240 |
Why?
|
| Endothelin-1 | 2 | 2017 | 40 | 0.240 |
Why?
|
| Quality Improvement | 3 | 2024 | 709 | 0.240 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2016 | 26 | 0.240 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 129 | 0.240 |
Why?
|
| Prevalence | 8 | 2020 | 2687 | 0.230 |
Why?
|
| Europe | 8 | 2020 | 366 | 0.230 |
Why?
|
| Electronic Health Records | 3 | 2025 | 816 | 0.230 |
Why?
|
| Myocardial Ischemia | 5 | 2006 | 309 | 0.220 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2025 | 39 | 0.220 |
Why?
|
| International Normalized Ratio | 1 | 2005 | 45 | 0.220 |
Why?
|
| Antibodies | 1 | 2026 | 320 | 0.220 |
Why?
|
| Pyridones | 2 | 2016 | 145 | 0.220 |
Why?
|
| Checklist | 1 | 2025 | 98 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2017 | 1223 | 0.210 |
Why?
|
| Craniocerebral Trauma | 1 | 2026 | 148 | 0.210 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2014 | 134 | 0.210 |
Why?
|
| Disinfection | 1 | 2024 | 24 | 0.210 |
Why?
|
| Internationality | 3 | 2020 | 128 | 0.210 |
Why?
|
| Clinical Laboratory Services | 1 | 2024 | 19 | 0.210 |
Why?
|
| Heart Ventricles | 1 | 2009 | 758 | 0.210 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3798 | 0.210 |
Why?
|
| Heparin | 5 | 2017 | 203 | 0.210 |
Why?
|
| Propensity Score | 4 | 2018 | 271 | 0.200 |
Why?
|
| Kidney Diseases | 3 | 2021 | 471 | 0.200 |
Why?
|
| Survival Analysis | 8 | 2015 | 1483 | 0.200 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2023 | 5 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2020 | 33 | 0.200 |
Why?
|
| Area Under Curve | 5 | 2018 | 305 | 0.200 |
Why?
|
| Chi-Square Distribution | 8 | 2016 | 565 | 0.200 |
Why?
|
| Ethics Committees, Research | 1 | 2023 | 29 | 0.200 |
Why?
|
| Odds Ratio | 10 | 2013 | 1210 | 0.190 |
Why?
|
| Albuterol | 1 | 2023 | 53 | 0.190 |
Why?
|
| Biomedical Research | 4 | 2016 | 562 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2025 | 233 | 0.190 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2026 | 103 | 0.190 |
Why?
|
| American Heart Association | 3 | 2022 | 338 | 0.190 |
Why?
|
| Pyrazoles | 2 | 2016 | 356 | 0.190 |
Why?
|
| Cardiotonic Agents | 3 | 2015 | 139 | 0.190 |
Why?
|
| Cholesterol, HDL | 1 | 2024 | 386 | 0.190 |
Why?
|
| Inpatients | 3 | 2017 | 558 | 0.190 |
Why?
|
| Emergencies | 2 | 2003 | 176 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 237 | 0.190 |
Why?
|
| Survival Rate | 9 | 2019 | 2112 | 0.190 |
Why?
|
| Multivariate Analysis | 9 | 2016 | 1376 | 0.190 |
Why?
|
| Infection Control | 1 | 2024 | 162 | 0.190 |
Why?
|
| Monocytes | 1 | 2024 | 336 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 2062 | 0.190 |
Why?
|
| Self Care | 2 | 2021 | 230 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2024 | 348 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2025 | 446 | 0.180 |
Why?
|
| Young Adult | 9 | 2026 | 9997 | 0.180 |
Why?
|
| Cause of Death | 6 | 2018 | 502 | 0.180 |
Why?
|
| Pain Clinics | 1 | 2021 | 5 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 297 | 0.180 |
Why?
|
| Systole | 3 | 2009 | 195 | 0.180 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 707 | 0.180 |
Why?
|
| Hospitals | 5 | 2022 | 437 | 0.180 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2021 | 33 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 547 | 0.180 |
Why?
|
| Physicians | 2 | 2008 | 635 | 0.180 |
Why?
|
| Neutrophils | 1 | 2024 | 361 | 0.180 |
Why?
|
| Case-Control Studies | 4 | 2026 | 3362 | 0.180 |
Why?
|
| Heart Conduction System | 3 | 2009 | 162 | 0.180 |
Why?
|
| Transgender Persons | 1 | 2022 | 69 | 0.170 |
Why?
|
| Naltrexone | 1 | 2021 | 70 | 0.170 |
Why?
|
| Medicare | 3 | 2017 | 440 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2009 | 1063 | 0.170 |
Why?
|
| Coronary Angiography | 4 | 2020 | 453 | 0.170 |
Why?
|
| Coronary Stenosis | 2 | 2015 | 78 | 0.170 |
Why?
|
| Laboratories | 2 | 2024 | 79 | 0.170 |
Why?
|
| Hospital Units | 3 | 2006 | 17 | 0.160 |
Why?
|
| Pyuria | 1 | 2000 | 6 | 0.160 |
Why?
|
| Neurophysiological Monitoring | 1 | 2021 | 37 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 4 | 2020 | 568 | 0.160 |
Why?
|
| Oliguria | 1 | 2000 | 20 | 0.160 |
Why?
|
| Blood Coagulation Tests | 2 | 2022 | 65 | 0.160 |
Why?
|
| Constipation | 1 | 2021 | 130 | 0.160 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2020 | 62 | 0.160 |
Why?
|
| Myoglobin | 2 | 2011 | 10 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 1 | 2021 | 112 | 0.160 |
Why?
|
| Buprenorphine | 1 | 2021 | 112 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2019 | 11 | 0.160 |
Why?
|
| Drug Antagonism | 1 | 2019 | 13 | 0.160 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2019 | 7 | 0.160 |
Why?
|
| Thrombolytic Therapy | 4 | 2011 | 197 | 0.160 |
Why?
|
| Antidotes | 1 | 2019 | 10 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2022 | 233 | 0.150 |
Why?
|
| Cystitis | 1 | 2000 | 47 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2019 | 65 | 0.150 |
Why?
|
| Risk | 2 | 2011 | 722 | 0.150 |
Why?
|
| Antithrombins | 1 | 2019 | 49 | 0.150 |
Why?
|
| Injections, Intravenous | 4 | 2017 | 236 | 0.150 |
Why?
|
| Adolescent | 16 | 2026 | 20733 | 0.150 |
Why?
|
| Heart Function Tests | 2 | 2017 | 50 | 0.150 |
Why?
|
| Health Status Indicators | 2 | 2010 | 112 | 0.150 |
Why?
|
| Critical Care | 4 | 2015 | 685 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 726 | 0.140 |
Why?
|
| Glucose | 1 | 2023 | 853 | 0.140 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 65 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 144 | 0.140 |
Why?
|
| Temperature | 1 | 2019 | 289 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 203 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 296 | 0.140 |
Why?
|
| Global Health | 4 | 2019 | 633 | 0.140 |
Why?
|
| Pain Measurement | 2 | 2017 | 349 | 0.130 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 14 | 0.130 |
Why?
|
| Blood Proteins | 2 | 2019 | 143 | 0.130 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 14 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 60 | 0.130 |
Why?
|
| Head | 1 | 2018 | 111 | 0.130 |
Why?
|
| Coronary Artery Bypass | 5 | 2014 | 515 | 0.130 |
Why?
|
| Telephone | 1 | 2018 | 110 | 0.130 |
Why?
|
| Medically Uninsured | 1 | 2018 | 79 | 0.130 |
Why?
|
| Respiration, Artificial | 3 | 2015 | 506 | 0.130 |
Why?
|
| Calcium Gluconate | 1 | 2017 | 7 | 0.130 |
Why?
|
| Potassium, Dietary | 1 | 2017 | 14 | 0.130 |
Why?
|
| Secondary Prevention | 2 | 2018 | 217 | 0.130 |
Why?
|
| Seasons | 1 | 2019 | 333 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 1074 | 0.130 |
Why?
|
| Finland | 1 | 2017 | 46 | 0.130 |
Why?
|
| New Zealand | 4 | 2019 | 60 | 0.130 |
Why?
|
| Transitional Care | 1 | 2017 | 17 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 225 | 0.130 |
Why?
|
| Motor Vehicles | 3 | 2021 | 10 | 0.130 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 229 | 0.130 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 50 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2023 | 889 | 0.120 |
Why?
|
| Iron | 1 | 2019 | 306 | 0.120 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 66 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 51 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 517 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 90 | 0.120 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 316 | 0.120 |
Why?
|
| Abdominal Pain | 1 | 2018 | 315 | 0.120 |
Why?
|
| Electroencephalography | 1 | 2021 | 846 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2011 | 955 | 0.120 |
Why?
|
| Intensive Care Units | 2 | 2018 | 526 | 0.120 |
Why?
|
| Administration, Inhalation | 2 | 2025 | 191 | 0.120 |
Why?
|
| Drug Utilization | 3 | 2012 | 163 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 2 | 2002 | 938 | 0.120 |
Why?
|
| Accidents, Traffic | 3 | 2021 | 105 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1487 | 0.120 |
Why?
|
| Natriuretic Peptides | 1 | 2015 | 9 | 0.120 |
Why?
|
| Heart | 1 | 2020 | 659 | 0.120 |
Why?
|
| Symptom Flare Up | 1 | 2015 | 25 | 0.120 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2004 | 61 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1611 | 0.110 |
Why?
|
| Smoking Cessation | 2 | 2014 | 191 | 0.110 |
Why?
|
| Thiazoles | 1 | 2015 | 111 | 0.110 |
Why?
|
| Disease Progression | 7 | 2020 | 2193 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2015 | 237 | 0.110 |
Why?
|
| Fibrosis | 2 | 2014 | 417 | 0.110 |
Why?
|
| Brain Concussion | 1 | 2017 | 248 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2015 | 89 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 229 | 0.100 |
Why?
|
| Quality of Life | 2 | 2021 | 2083 | 0.100 |
Why?
|
| Renal Dialysis | 2 | 2002 | 948 | 0.100 |
Why?
|
| Data Collection | 2 | 2013 | 370 | 0.100 |
Why?
|
| Patient Selection | 3 | 2008 | 720 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2017 | 382 | 0.100 |
Why?
|
| Radiography, Thoracic | 3 | 2014 | 145 | 0.100 |
Why?
|
| Syndrome | 6 | 2009 | 1159 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2016 | 443 | 0.100 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 28 | 0.100 |
Why?
|
| Internet | 2 | 2007 | 421 | 0.100 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 425 | 0.100 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2014 | 86 | 0.100 |
Why?
|
| Electric Impedance | 2 | 2011 | 71 | 0.100 |
Why?
|
| Cardiac Care Facilities | 2 | 2015 | 11 | 0.100 |
Why?
|
| Recurrence | 3 | 2019 | 1472 | 0.100 |
Why?
|
| Ventricular Remodeling | 1 | 2014 | 153 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2025 | 2568 | 0.100 |
Why?
|
| Body Surface Potential Mapping | 2 | 2010 | 18 | 0.100 |
Why?
|
| Ohio | 4 | 2005 | 85 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 684 | 0.100 |
Why?
|
| Monitoring, Physiologic | 2 | 2021 | 372 | 0.100 |
Why?
|
| Thromboembolism | 1 | 2013 | 94 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2015 | 288 | 0.090 |
Why?
|
| Radiology | 2 | 2016 | 119 | 0.090 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2012 | 44 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2013 | 1676 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2012 | 91 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2014 | 180 | 0.090 |
Why?
|
| Software | 1 | 2017 | 731 | 0.090 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2025 | 60 | 0.090 |
Why?
|
| Inflammation | 2 | 2023 | 1485 | 0.090 |
Why?
|
| Cardiac Output | 2 | 2010 | 154 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2014 | 217 | 0.090 |
Why?
|
| Blood Urea Nitrogen | 2 | 2009 | 69 | 0.090 |
Why?
|
| Veterans | 3 | 2019 | 1754 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2015 | 524 | 0.090 |
Why?
|
| Morbidity | 2 | 2010 | 257 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 213 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2011 | 16 | 0.080 |
Why?
|
| Laryngeal Masks | 1 | 2011 | 16 | 0.080 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2010 | 5 | 0.080 |
Why?
|
| Endotoxins | 1 | 2011 | 51 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 1217 | 0.080 |
Why?
|
| Enoxaparin | 2 | 2017 | 43 | 0.080 |
Why?
|
| Kidney Function Tests | 2 | 2008 | 136 | 0.080 |
Why?
|
| Myocardium | 2 | 2010 | 857 | 0.080 |
Why?
|
| Dihydropyridines | 1 | 2010 | 6 | 0.080 |
Why?
|
| Posture | 1 | 2010 | 135 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2004 | 319 | 0.080 |
Why?
|
| Hypotension | 2 | 2017 | 183 | 0.080 |
Why?
|
| Vascular Resistance | 1 | 2010 | 182 | 0.080 |
Why?
|
| France | 2 | 2019 | 90 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2013 | 554 | 0.080 |
Why?
|
| Singapore | 4 | 2016 | 16 | 0.080 |
Why?
|
| Likelihood Functions | 2 | 2006 | 115 | 0.080 |
Why?
|
| Decision Trees | 2 | 2016 | 57 | 0.070 |
Why?
|
| Texas | 1 | 2018 | 3643 | 0.070 |
Why?
|
| Electric Countershock | 1 | 2009 | 75 | 0.070 |
Why?
|
| Information Services | 1 | 2009 | 23 | 0.070 |
Why?
|
| House Calls | 2 | 2021 | 35 | 0.070 |
Why?
|
| Cardiovascular System | 1 | 2010 | 98 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 311 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2009 | 277 | 0.070 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 102 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2009 | 936 | 0.070 |
Why?
|
| Alcoholism | 1 | 1990 | 244 | 0.070 |
Why?
|
| Methamphetamine | 1 | 2008 | 46 | 0.070 |
Why?
|
| Echocardiography | 2 | 2020 | 1127 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2008 | 130 | 0.070 |
Why?
|
| Australia | 2 | 2019 | 171 | 0.060 |
Why?
|
| Contraindications | 1 | 2007 | 75 | 0.060 |
Why?
|
| Cocaine | 1 | 2008 | 209 | 0.060 |
Why?
|
| Pulmonary Edema | 2 | 2005 | 55 | 0.060 |
Why?
|
| Heart Murmurs | 1 | 2006 | 12 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2006 | 76 | 0.060 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2017 | 17 | 0.060 |
Why?
|
| Exercise | 1 | 2012 | 862 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2004 | 140 | 0.060 |
Why?
|
| Asia | 2 | 2020 | 125 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2011 | 501 | 0.060 |
Why?
|
| Linear Models | 2 | 2013 | 686 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 453 | 0.060 |
Why?
|
| Specialties, Nursing | 1 | 2005 | 4 | 0.060 |
Why?
|
| Healthy Volunteers | 1 | 2026 | 154 | 0.060 |
Why?
|
| Tertiary Care Centers | 2 | 2017 | 248 | 0.060 |
Why?
|
| Medicaid | 1 | 2008 | 251 | 0.060 |
Why?
|
| Creatinine | 4 | 2014 | 396 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2026 | 89 | 0.060 |
Why?
|
| Documentation | 2 | 2004 | 121 | 0.060 |
Why?
|
| Hospital Bed Capacity | 2 | 2016 | 29 | 0.050 |
Why?
|
| Vitamin K | 1 | 2005 | 35 | 0.050 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2005 | 85 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2026 | 191 | 0.050 |
Why?
|
| Age Distribution | 3 | 2015 | 422 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 36 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2004 | 46 | 0.050 |
Why?
|
| Point-of-Care Testing | 1 | 2024 | 33 | 0.050 |
Why?
|
| Home Care Services | 1 | 2024 | 69 | 0.050 |
Why?
|
| Obesity | 2 | 2013 | 2381 | 0.050 |
Why?
|
| Economics, Hospital | 1 | 2003 | 7 | 0.050 |
Why?
|
| Coronary Thrombosis | 1 | 2003 | 33 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2024 | 247 | 0.050 |
Why?
|
| Diastole | 1 | 2004 | 181 | 0.050 |
Why?
|
| HIV Infections | 1 | 2016 | 2032 | 0.050 |
Why?
|
| Shock, Cardiogenic | 2 | 2015 | 172 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2004 | 136 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 137 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2016 | 485 | 0.050 |
Why?
|
| Physical Examination | 3 | 2014 | 164 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2004 | 116 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2016 | 25 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 88 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2023 | 150 | 0.050 |
Why?
|
| Fractures, Bone | 2 | 1995 | 215 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 249 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 226 | 0.050 |
Why?
|
| Kansas | 1 | 2021 | 6 | 0.040 |
Why?
|
| Prescriptions | 1 | 2021 | 44 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2000 | 785 | 0.040 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2021 | 35 | 0.040 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2020 | 25 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 151 | 0.040 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2020 | 47 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 704 | 0.040 |
Why?
|
| Blood Culture | 1 | 2020 | 37 | 0.040 |
Why?
|
| Uterine Hemorrhage | 1 | 2020 | 41 | 0.040 |
Why?
|
| Medical Records | 2 | 2006 | 175 | 0.040 |
Why?
|
| Netherlands | 1 | 2019 | 50 | 0.040 |
Why?
|
| Georgia | 1 | 2019 | 46 | 0.040 |
Why?
|
| Radiography | 3 | 2016 | 743 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 56 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 372 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 352 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 759 | 0.040 |
Why?
|
| Judgment | 1 | 2018 | 37 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 20 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 1391 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 128 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 204 | 0.030 |
Why?
|
| Telemedicine | 2 | 2021 | 522 | 0.030 |
Why?
|
| Patient Discharge Summaries | 1 | 2017 | 6 | 0.030 |
Why?
|
| Military Personnel | 1 | 2019 | 210 | 0.030 |
Why?
|
| Forecasting | 2 | 2014 | 350 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 1456 | 0.030 |
Why?
|
| Narcotics | 1 | 2017 | 59 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 410 | 0.030 |
Why?
|
| Probability | 2 | 2009 | 305 | 0.030 |
Why?
|
| Athletic Injuries | 1 | 2017 | 75 | 0.030 |
Why?
|
| Vital Signs | 1 | 2016 | 24 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 1996 | 26 | 0.030 |
Why?
|
| Smoking | 2 | 2012 | 928 | 0.030 |
Why?
|
| Angiography | 1 | 2016 | 181 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 4029 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 164 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 79 | 0.030 |
Why?
|
| Health Personnel | 2 | 2014 | 550 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2018 | 268 | 0.030 |
Why?
|
| Foot Injuries | 1 | 1995 | 11 | 0.030 |
Why?
|
| Knee Injuries | 1 | 1995 | 36 | 0.030 |
Why?
|
| Pravastatin | 1 | 2015 | 22 | 0.030 |
Why?
|
| Ankle Injuries | 1 | 1995 | 31 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 111 | 0.030 |
Why?
|
| Nurse's Role | 1 | 2015 | 34 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 237 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 138 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 182 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2014 | 24 | 0.030 |
Why?
|
| Vascular Calcification | 1 | 2015 | 69 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2006 | 318 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 144 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 347 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 150 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 282 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 291 | 0.030 |
Why?
|
| Public Health | 1 | 2016 | 272 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 1167 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2014 | 195 | 0.020 |
Why?
|
| European Union | 1 | 2012 | 13 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 713 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2017 | 559 | 0.020 |
Why?
|
| Pneumonia, Aspiration | 1 | 1992 | 18 | 0.020 |
Why?
|
| Pharynx | 1 | 1992 | 65 | 0.020 |
Why?
|
| Oxygen | 1 | 2015 | 552 | 0.020 |
Why?
|
| Depression | 1 | 2020 | 1316 | 0.020 |
Why?
|
| Foreign Bodies | 1 | 1992 | 96 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2011 | 14 | 0.020 |
Why?
|
| England | 1 | 2011 | 58 | 0.020 |
Why?
|
| Emergency Medical Technicians | 1 | 2011 | 34 | 0.020 |
Why?
|
| Americas | 1 | 2011 | 52 | 0.020 |
Why?
|
| Evidence-Based Emergency Medicine | 1 | 2010 | 3 | 0.020 |
Why?
|
| Italy | 1 | 2011 | 114 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 813 | 0.020 |
Why?
|
| Intubation | 1 | 1990 | 16 | 0.020 |
Why?
|
| History, 19th Century | 1 | 2011 | 110 | 0.020 |
Why?
|
| California | 1 | 2010 | 126 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 161 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 1992 | 173 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2009 | 28 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 130 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 194 | 0.020 |
Why?
|
| Atrial Flutter | 1 | 2009 | 45 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2011 | 363 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 56 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1990 | 272 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 536 | 0.020 |
Why?
|
| Education | 1 | 2009 | 112 | 0.020 |
Why?
|
| Esophagus | 1 | 1990 | 231 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 744 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 78 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 73 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3180 | 0.020 |
Why?
|
| Crowding | 1 | 2007 | 12 | 0.020 |
Why?
|
| Benchmarking | 1 | 2008 | 135 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 694 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 1990 | 287 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 454 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 25 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2008 | 166 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2015 | 1013 | 0.020 |
Why?
|
| Lipids | 1 | 2010 | 558 | 0.010 |
Why?
|
| Anemia | 1 | 2009 | 351 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2010 | 1240 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2008 | 481 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 342 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 222 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2010 | 796 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 227 | 0.010 |
Why?
|
| Sodium | 1 | 2005 | 279 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2005 | 286 | 0.010 |
Why?
|
| Factor Xa | 1 | 2004 | 15 | 0.010 |
Why?
|
| Stents | 1 | 2009 | 781 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 323 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2003 | 243 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2004 | 321 | 0.010 |
Why?
|
| Telemetry | 1 | 2000 | 22 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 1999 | 62 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1999 | 138 | 0.010 |
Why?
|
| Suburban Health Services | 1 | 1996 | 1 | 0.010 |
Why?
|
| Michigan | 1 | 1996 | 47 | 0.010 |
Why?
|
| Ontario | 1 | 1995 | 84 | 0.010 |
Why?
|
| Physicians, Women | 1 | 1996 | 53 | 0.010 |
Why?
|
| Women's Health | 1 | 1996 | 133 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1994 | 43 | 0.010 |
Why?
|
| Emergency Services, Psychiatric | 1 | 1994 | 23 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1990 | 33 | 0.010 |
Why?
|
| Heart Massage | 1 | 1990 | 29 | 0.000 |
Why?
|
| Dogs | 1 | 1990 | 617 | 0.000 |
Why?
|
| Models, Biological | 1 | 1990 | 1384 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1994 | 14964 | 0.000 |
Why?
|
| Child | 1 | 1994 | 26119 | 0.000 |
Why?
|
| Animals | 1 | 1990 | 33849 | 0.000 |
Why?
|